In gastric and colon cancers, fibroblast activation protein (FAP) in CAFs leads to more CCL2 and less IFN-γ, eventually damaging the outcome of ICIs therapy (Chen et al., 2017), while FAP Inhibition reverses this resistance (Wen et al., 2017). This evidence concerns the gene FAP and colonic neoplasm.